

Ernst & Young Vietnam Limited

Bitexco Financial Tower 28th Floor, 2 Hai Trieu Street District 1, Ho Chi Minh City, S.R. of Vietnam

Tel: +84 8 3824 5252 Fax: +84 8 3824 5250 www.ev.com/vn

Reference: 60758390/15286588

INDEPENDENT AUDITORS' REPORT

To: The Shareholders of ICA Biotechnological – Pharmaceuticals Joint Stock Company

We have audited the consolidated financial statements of ICA Biotechnological – Pharmaceuticals Joint Stock Company and its subsidiaries (the "Group") as set out on pages 4 to 38 which comprise the consolidated balance sheet as at 31 December 2011, the consolidated income statement and the consolidated cash flow statement for the year then ended and the notes thereto.

The preparation and presentation of these consolidated financial statements are the responsibility of the Group's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

Basis of opinion

We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the Group's management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

Opinion

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2011, and of the consolidated results of its operations and its consolidated cash flows for the year then ended in accordance with the Vietnamese Accounting Standards and System and comply with the relevant statutory requirements.

Vietnam∰ imited

Mai Viet Hung Tran Deputy General Director

Certificate No. D.0048/KTV

Auditor

Hang Nhat Quang

Certificate No. N.1772/KT

Ho Chi Minh City, Vietnam

30 September 2012

ICA Biotechnological – Pharmaceutical Joint Stock Company B01-DN/HN

CONSOLIDATED BALANCE SHEET as at 31 December 2011

VND

				VND
Code	ASSETS	Notes	Ending balance	Beginning balance
100	A. CURRENT ASSETS		242,755,641,412	218,076,643,420
110	I. Cash		3,708,063,758	6,889,554,338
111	1. Cash	4	3,708,063,758	6,889,554,338
130	II. Current accounts receivable		211,462,419,265	189,072,707,066
131	 Trade receivables 		65,848,344,262	93,035,782,106
132	Advances to suppliers		24,042,288,960	22,349,077,072
135	3. Other receivables	5	121,571,786,043	73,687,847,888
140	III. Inventories	6	19,573,963,118	14,948,463,292
141 149	Inventories Provision for obsolete		21,580,358,631	18,441,650,840
, 10	inventories		(2,006,395,513)	(3,493,187,548)
150	IV. Other current assets		8,011,195,271	7,165,918,724
151	 Short-term prepaid expenses 		722,723,066	742,153,483
152 154	Value-added tax deductible Tax and other receivables		2,622,051,622	4,170,493,847
	from the State		203,142,194	203,142,194
158	4. Other current assets	7	4,463,278,389	2,050,129,200
200	B. NON-CURRENT ASSETS		385,337,373,258	415,331,511,965
220	I. Fixed assets		260,461,566,080	283,884,596,115
221	 Tangible fixed assets 	8	20,704,659,347	26,558,394,953
222	Cost		76,500,301,924	77,917,846,890
223	Accumulated depreciation		(55,795,642,577)	(51,359,451,937)
227	Intangible fixed assets	9	227,357,858,709	244,927,153,138
228	Cost		322,522,435,501	322,522,435,501
229	Accumulated amortisation		(95, 164, 576, 792)	(77,595,282,363)
230	Construction in progress	10	12,399,048,024	12,399,048,024
260	II. Other long-term assets		14,195,817,821	6,931,927,823
261	 Long-term prepaid expenses 	11	4,177,956,103	4,338,443,452
262	Deferred tax assets	24.2	9,563,546,463	2,139,169,116
268	Other long-term assets		454,315,255	454,315,255
269	III. Goodwill	12	110,679,989,357	124,514,988,027
270	TOTAL ASSETS		628,093,014,670	633,408,155,385

ICA Biotechnological – Pharmaceutical Joint Stock Company B01-DN/HN

CONSOLIDATED BALANCE SHEET (continued) as at 31 December 2011

VND

				VNL
Code	RESOURCES	Notes	Ending balance	Beginning balance
300	A. LIABILITIES		428,148,850,247	406,524,505,786
310	I. Current liabilities		397,703,458,598	364,141,455,037
311	Short-term loans	13	166,439,085,412	165,752,260,092
312	Trade payables		59,117,010,182	74,039,831,011
313	Advances from customers		9,222,728,540	268,611,812
314	 Statutory obligations 	14	45,335,249,534	43,346,539,462
315	Payables to employees		2,348,485,568	3,529,093,590
316	Accrued expenses	15	35,028,078,836	20,452,124,418
319	7. Other payables	16	69,380,688,747	46,250,984,540
323	Bonus and welfare fund		10,832,131,779	10,502,010,112
330	II. Non-current liabilities		30,445,391,649	42,383,050,749
331	 Long-term trade payables 		6,248,400,000	7,572,800,000
333	Other long-term liabilities		290,000,000	250,000,500
334	Long-term loans	17	20,283,307,500	31,105,000,000
336	 Provision for severance 			
	allowance		3,623,684,149	3,455,250,249
400	B. OWNERS' EQUITY	18.1	199,919,652,857	226,862,046,714
410	I. Capital		199,919,652,857	226,862,046,714
411	Share capital	18.2	116,500,000,000	116,500,000,000
412	Share premium		13,475,000,000	13,475,000,000
416	Foreign exchange difference	ces		
417	reserve 4. Investment and developme	nt	(3,551,894,418)	-
717	fund	1111	27,437,774,724	22,421,624,675
418	5. Financial reserve fund		11,555,505,011	9,047,429,987
419	6. Other funds belonging to		11,000,000,011	3,041,423,301
713	owners' equity		4,326,764,700	4,326,764,700
420	7. Undistributed earnings		30,176,502,840	61,091,227,352
720	7. Olidistributed cultilligs		30,170,302,040	01,031,221,332
439	C. MINORITY INTERESTS		24,511,566	21,602,885
440	TOTAL LIABILITIES AND			
	OWNERS' EQUITY		628,093,014,670	633,408,155,385

Bui Thi Mai Huong Chief Accountant

Luong Quang Son General Director

CÔNG NGHỆ SINH

30 September 2012

ICA Biotechnological - Pharmaceutical Joint Stock Company B02-DN/HN

CONSOLIDATED INCOME STATEMENT for the year ended 31 December 2011

				VND
Code	ITEMS	Notes	Current year	Previous year
01	Revenue from sale of goods	19.1	247,483,577,866	346,175,732,505
02	2. Deductions	19.1	(18,595,504,886)	(188,894,420)
10	3. Net revenue from sale of goods	19.1	228,888,072,980	345,986,838,085
11	4. Cost of goods sold	20, 22	(108,847,294,099)	(163,493,589,179)
20	5. Gross profit		120,040,778,881	182,493,248,906
21	6. Finance income	19.2	477,431,700	1,768,014,142
22 23	7. Finance expenses In which: Interest expense	21	(32,285,762,627) (26,781,870,464)	(23,840,392,589) (20,815,841,548)
24	8. Selling expenses	22	(29,889,939,798)	(50,120,723,090)
25	General and administrative expenses	22	(54,776,857,148)	(58,330,611,009)
30	10. Operating profit		3,565,651,008	51,969,536,360
31	11. Other income	23	2,543,730,930	1,195,755,645
32	12. Other expenses	23	(1,398,945,269)	(120,940,685)
40	13. Other profit	23	1,144,785,661	1,074,814,960
50	14. Profit before tax		4,710,436,669	53,044,351,320
51	15. Current income tax expense	24.1	(4,698,179,701)	(4,669,640,988)
52	16. Deferred income tax benefit	24.2	7,424,377,347	1,791,893,709
60	17. Net profit after tax In which:		7,436,634,315	50,166,604,041
61 62	17.1. Minority interest 17.2. Equity holders of the parent		2,908,681 7,433,725,634	5,103,553 50,161,500,488
80	18. Basic earnings per share	18.4	13700335517.	4,306

Bui Thi Mai Huong Chief Accountant Luong Quang Son General Director

CỔ PHẨM CÓNG NGHỆ MH

30 September 2012

ICA Biotechnological - Pharmaceutical Joint Stock Company B03-DN/HN

CONSOLIDATED CASH FLOW STATEMENT for the year ended 31 December 2011

Code	ITEMS	Notes	Current year	Previous year
	I. CASH FLOWS FROM			
	OPERATING ACTIVITIES			
01	Profit before tax		4,710,436,669	53,044,351,320
	Adjustments for:		1869 - 1864 - 1865	
02	Depreciation and amortisation	8, 9, 12	37,122,559,186	48,290,343,694
03	Provisions		(1,486,792,035)	2,378,607,816
04	Unrealised foreign exchange			
	losses	21	1,118,426,397	440,987,234
05	Profits from investing activities		(355,407,091)	(182,079,780)
06	Interest expense	21	26,781,870,464	20,815,841,548
08	Operating profit before changes			
	in working capital		67,891,093,590	124,788,051,832
09	Increase in receivables		(22,286,702,498)	(96,725,225,463)
10	(Increase) decrease in			*
	inventories		(3,138,707,791)	27,617,847,797
11	(Decrease) increase in			
	payables		(8,759,949,657)	6,974,384,471
12	Decrease (increase) in prepaid			
40	expenses		179,917,766	(270,510,495)
13	Interest paid		(16,723,707,503)	(15,464,796,547)
16	Other cash outflows from		(4 005 040 540)	/E 40E 400 70E\
	operating activities		(1,225,919,542)	(5,135,162,705)
20	Net cash flows from operating			
	activities		15,936,024,365	41,784,588,890
	II. CASH FLOWS FROM			
	INVESTING ACTIVITIES			
21	Purchase of fixed assets		(199,125,190)	(705,239,145)
22	Proceeds from disposals of		(100,120,100)	(100,200,110)
	fixed assets		545,454,545	-
28	Interest received		144,547,255	182,079,780
30	Net cash flows from (used in)			
30	investing activities		490,876,610	(523,159,365)
				· · · · · · · · · · · · · · · · · · ·
	III. CASH FLOWS FROM			
	FINANCING ACTIVITIES			
33	Drawdown of borrowings		87,066,018,460	74,572,667,406
34	Repayment of borrowings		(99,901,398,140)	(115,690,562,651)
36	Dividends paid		(6,773,011,875)	·-
40	Net cash flows used in financing			
	activities		(19,608,391,555)	(41,117,895,245)
	uotivitios		(10,000,001,000)	(71,117,095,24

ICA Biotechnological - Pharmaceutical Joint Stock Company B03-DN/HN

CONSOLIDATED CASH FLOW STATEMENT (continued) for the year ended 31 December 2011

VND

Code	ITEMS	Notes	Current year	Previous year
50	Net (decrease) increase in cash		(3,181,490,580)	143,534,280
60	Cash at beginning of year	4	6,889,554,338	6,746,020,058
70	Cash at end of year	4	3,708,063,758	6,889,554,338

Bui Thi Mai Huong Chief Accountant

30 September 2012

Luong Quang Son General Director

CÔNG NGHỆ SỰ